HC Wainwright & Co. Reiterates Buy on Aurinia Pharmaceuticals, Maintains $13 Price Target
Portfolio Pulse from Benzinga Newsdesk
HC Wainwright & Co. analyst Ed Arce reiterates a Buy rating on Aurinia Pharmaceuticals (NASDAQ:AUPH) with a maintained price target of $13.
March 01, 2024 | 7:09 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Aurinia Pharmaceuticals receives a reiterated Buy rating and a maintained $13 price target from HC Wainwright & Co.
The reiteration of a Buy rating and maintenance of a $13 price target by a reputable analyst firm like HC Wainwright & Co. typically signals a strong vote of confidence in the company's future performance. This endorsement is likely to positively influence investor sentiment and potentially lead to a short-term increase in the stock price of Aurinia Pharmaceuticals.
CONFIDENCE 95
IMPORTANCE 90
RELEVANCE 100